

# Misonix, Inc. (Nasdaq: MSON)

## Medical Appliances & Equipment

December 2015


### Company Statistics (as of 12/02/15)

Stock Price:	\$9.37
52 Week Range:	\$8.20 - \$14.50
Market Capitalization:	\$72.62M
Avg. Daily Vol. (3 mos.):	16,189
Long-term Debt:	\$0
Shares Outstanding:	7.75M
Total Cash/Share:	\$1.25
Enterprise Value:	\$63.22M


### Financial Summary

Rev	2012A	2013A	2014A	2015A	2016A
Q1	\$3.217	\$4.571	\$3.076	\$4.539	\$5.251
Q2	\$3.551	\$3.474	\$4.122	\$5.601	
Q3	\$3.610	\$3.023	\$4.285	\$5.315	
Q4	\$5.301	\$3.759	\$5.578	\$6.749	
FY Jun	\$15.678	\$14.827	\$17.060	\$22.205	
EPS	2012A	2013A	2014A	2015A	2016A
Q1	\$(0.11)	\$0.01	\$(0.12)	\$0.05	\$(0.03)
Q2	\$0.03	\$(0.09)	\$0.06	\$0.11	
Q3	\$(0.04)	\$(0.09)	\$0.05	\$0.05	
Q4	\$0.03	\$(0.22)	\$0.18	\$0.46	
FY Jun	\$(0.09)	\$(0.38)	\$0.19	\$0.69	

### Revenue (\$ in Millions)



### Gross Margins



### Company Description

Misonix designs, manufactures and markets leading-edge ultrasonic surgical tools for a global market that approximates \$1.5 BILLION annually.

Misonix utilizes a “razor / razorblade” model and currently generates recurring revenue in the mid-50% range. Since 2010 net sales have grown at a 17% compounded annual rate.

The use of the Misonix BoneScalpel, primarily for spinal procedures, provides orthopedic surgeons greater control and accuracy in making precise cuts, with less blood loss while sparing soft tissue. The action of the BoneScalpel’s 22,500 per second retracting blade precisely cuts bone and bounces off soft tissue with no damage. The Company’s SonicOne O.R. is a highly innovative ultrasonic tool to treat burn and diabetic wounds for more effective recovery. The Misonix SonaStar selectively fragments, emulsifies and aspirates unwanted soft and hard tissue, while leaving vital nerves and blood vessel unaffected. The Company’s products are consistently gaining broader acceptance by surgical professionals throughout the world and are often recognized at global surgical and medical conferences.

### Misonix First Quarter 2016 Update

In the Company’s earnings press release issued on November 5, 2015, Misonix reported the following first quarter fiscal year 2016 financial highlights:


- Net sales for first quarter fiscal 2016 were \$5.3 million, a 16% increase, compared to \$4.5 million for the same period in fiscal 2015.
- BoneScalpel revenue increased 30% to \$2.9 million versus \$2.2 million in the first quarter of fiscal 2015.
- BoneScalpel units sold or consigned worldwide in first quarter fiscal 2016 totaled 53 compared to 56 systems for the first quarter of fiscal 2015.
- BoneScalpel revenue in the United States increased 64% to \$1.8 million in the first quarter fiscal 2016 compared to \$1.1 million during first quarter fiscal 2015.
- BoneScalpel disposables revenue in the U.S. increased 96% to \$1.6 million versus \$842,000 in the first quarter of fiscal 2015. BoneScalpel disposable unit sales in the U.S. increased 104% to 7,029 from 3,449 units in the first quarter of fiscal 2015.
- SonicOne first quarter 2016 revenue increased 43% to \$859,000 compared to \$601,000 in the first quarter of fiscal 2015. SonicOne OR revenue increased 98% to \$647,000.
- Recurring revenue – comprised of BoneScalpel, SonaStar® and SonicOne disposables sales - totaled \$3.6 million, or 69% of total first quarter fiscal 2016 revenue, as compared to \$2.4 million, or 54% of first quarter fiscal 2015 sales.

**THIS IS NOT A RESEARCH REPORT. ALL INFORMATION IS DERIVED FROM COMPANY PRESS RELEASES, SEC DOCUMENTS OR OTHER PUBLICLY AVAILABLE SOURCES.**


Lytham Partners, LLC (“Lytham”) provides a range of investor relations services to its clients. The particular services provided vary by client and may change from time to time. Lytham’s services are designed to increase client companies’ exposure to, and awareness by, broker/dealers and other members of the professional investment community. Lytham is compensated for providing investor relations services by its clients. Please see the important disclosures on the last page of this report.

### BoneScalpel

# of Units Sold/Placed



# of Consumables Sold



\*Includes both blades and tube sets




The BoneScalpel is a unique, state of the art, ultrasonic bone cutting system capable of making precise cuts with minimal necrosis, minimal burn artifact, minimal inflammation and minimal bone loss. The device is also capable of preserving surrounding soft tissue structures. The effect on surrounding soft tissue is minimal due to the elastic and flexible structure of healthy tissue. This is a significant advantage in anatomical regions like the spine where patient safety is of primary concern. In addition, the linear motion of the blunt, tissue-impacting tips, 22,500 times per second, avoids accidental ‘trapping’ of soft tissue while largely eliminating the high speed spinning and tearing associated with rotary power instruments.


The BoneScalpel allows surgeons to improve on existing surgical techniques by creating new approaches to osteotomies and bone removal, leading to substantial time savings and increased operation efficiencies.

### SonicOne System

# of Units Sold/Placed



# of Consumables Sold



\*Includes both blades and tube sets




The Sonic O.R. System is a highly innovative ultrasonic surgical tool to effectively treat diabetic ulcers and wounds resulting from burns sustained in fires, scalding incidents and industrial accidents. The Sonic O.R. effectively removes necrotic tissue and fibrin deposits while sparing viable, surrounding cellular structures. The tissue specific capability is, in part, due to the fact that healthy and viable tissue structures have a higher elasticity and flexibility than necrotic tissue and are more resistant to destruction from the impact effects of ultrasound. The therapeutic effects of low frequency ultrasound on wound bed preparation and healing is well documented in medical literature. Ultrasound has been shown to have antimicrobial effects that contribute to the destruction of bacteria and biofilm in wounds, thereby accelerating the progression toward full patient healing.


In 2012, there were 26 million diabetic patients in the US in and 285 million patients globally. Of these patients, approximately 15% will develop a diabetic foot ulcer and 50% of these will become infected, representing an estimated 2 million patients. The diabetic foot ulcer is the most common cause of non-traumatic lower extremity amputations in the US and Europe: there is an average of 82,000 amputations per year in the U.S., costing an estimated \$1.6 billion annually. The estimated cost of foot ulcer care in the U.S. is estimated to be as high as \$5 billion. With regards to burns, data from the National Center for Injury Prevention and Control in the U.S. show that approximately 2 million fires are reported each year which result in 1.2 million people with burn injuries. Moderate to severe burn injuries requiring hospitalization account for approximately 100,000 cases and about 5,000 patients die each year from burn-related complications, resulting in multi-billion annual treatment costs.

## SonaStar Ultrasonic System

### # of Units Sold/Placed



### # of Consumables Sold



\*Includes all disposables



The SonaStar System provides powerful precise aspiration following the ultrasonic ablation of hard or soft tissue. The SonaStar has been used for a wide variety of surgical procedures using both open and minimally invasive approaches, including neurosurgery and liver surgery. An additional option for the SonaStar is the use of OsteoSculpt® probe tips, which allows for the precise shaping or shaving of bony structures that prevent open access to partially or completely hidden soft tissue masses.

The Misonix SonaStar® is capable of selectively fragmenting, emulsifying and aspirating unwanted soft and hard tissue i.e. bone, while leaving vital nerves and blood vessels unaffected. Growth in the number of neurosurgery procedures and other surgeries such as general (liver) is driving the ultrasonic aspirator worldwide market with considerable interest in systems such as the SonaStar® Ultrasonic Aspirator. The SonaStar® total addressable market is \$120M worldwide.

The Misonix SonaStar® Ultrasonic Aspirator is an ideal choice for the surgical intervention of such neurosurgical procedures as:

- Skull/non-skull base tumor resections (SonaStar® Aspiration Tips)
- Transnasal [MIS] procedures (SonaStar® Deep Access Probes)
- Acoustic meningiomas (SonaStar® OsteoSculpt® Bone Shavers)

Additionally, the SonaStar® Ultrasonic Aspirator is also commonly used to safely and efficiently ablate tumors of the liver. It is estimated that globally, there are over 7,000 liver tumor resection surgeries each year.

## MSON Sales & Marketing

### Domestic – Hybrid Sales Organization

- 51 Surgical Distributors
- 30 Wound Distributors
- Supported by:
  - Surgical - Misonix Sales Director, Regional Sales Managers (4), Clinical Specialists (4)
  - Wound – Regional Sales Managers (2), Trainer (3)

### International – Specialty Distributor Organization

- 45 Specialty Distributors with over 200 salespeople
- Supported by Misonix Sales Directors (2) and Application Specialists (2)

In the United States, a nationwide ‘hybrid’ sales organization, which includes contracted, commissioned, independent sales representatives, managed by Company personnel and supported by Company applications specialists, markets the Company’s neuro/spine/skull-based products to its surgical customers. Products in this category are the SonaStar and Bone Scalpel Systems. A similar nationwide ‘hybrid’ sales organization is utilized to market the Company’s wound care product portfolio to its acute, in-patient and clinic customer base. Products in this category are SonicOne and SonicOne O.R.

Outside the United States, the BoneScalpel and SonaStar product platforms are marketed by specialty distributors who purchase products from the Company and resell products to their clinical customer bases. These product platforms have a strong presence in all major markets in the Americas, Europe, the Middle East, Asia, Australia and New Zealand. With regard to the SonicOne, the primary market presently is in the United States.

## Ultrasonic Technology

Therapeutic ultrasound is an advanced technology with very unique characteristics that can improve surgeries around the world. Ultrasonic tools used in surgery are able to remove specifically targeted structures on a microscopic, even cellular level. Diseased tissues can be removed while important nerves in the proximity are spared. Collateral damage is kept minimal. Bleeding can be reduced and with the appropriate tool even stopped. Harmful bacteria can be destroyed and infection-causing biofilms, like caries causing plaque, can be reduced. The formation of cell regrowth in open wounds can increase as can healing rates and patient outcomes.

## Addressable Markets

	Market Segment	Surgical Specialties	Current Standard	Market Size U.S.	Market Size Worldwide	
Neuro / Spine	BoneScalpel™	Spine	Orthopedics & Neurosurgical	High-speed Burr	\$ 321 M	\$ 640 M
	SonaStar®	Tumor Resection	Neurosurgical	Ultrasonic Aspirator	\$ 37 M	\$ 120 M <i>(includes liver surgery)</i>
	<b>Total</b>				<b>\$ 358 M</b>	<b>\$ 760 M</b>

	Market Segment	Surgical Specialties	Current Standard	Market Size U.S.	Market Size Worldwide	
Wound	SonicOne®	Wound Debridement	Plastic Reconstructive General Vascular Podiatric	Waterjet Scalpel, Curette	\$328 M	\$ 850 M

## Recent Key Developments

11/23/15

### Misonix Conducts National Distributor Training Program For SonicOne® O.R. At The 28th Annual Southern Regional Burn Conference

MISONIX unveiled a newly redesigned SonicOne O.R. device and hand piece at the Southern Regional Burn Conference in Dallas, Texas.

11/11/15

### Misonix Trains More Than 50 Spine Surgeons At 2015 Society For Minimally Invasive Spine Surgery Annual Meeting

MISONIX successfully introduced the new BoneScalpel® MIS Platform to more than 50 of the world's leading minimally invasive spine surgeons, including various surgeon key opinion leaders ("KOLs") last week at the annual Society for Minimally Invasive Spine Surgery ("SMISS") meeting in Las Vegas, NV.

11/11/15

### Misonix to Present at the Stifel 2015 Healthcare Conference

MISONIX announced that Michael A. McManus, Jr., Chief Executive Officer, and Richard Zarembo, Chief Financial Officer, will present at the Stifel 2015 Healthcare Conference on Tuesday, November 17, 2015 at 9:30 am ET.

11/05/15

### Misonix, Inc. Announces First Quarter Fiscal Year 2016 Financial Results

Misonix announced financial results for the first quarter of fiscal year 2016 ended September 30, 2015.

10/21/15

### Misonix Introduces BoneScalpel® MIS Platform and Trains More Than 120 Surgeons At The 2015 North American Spine Society Annual Meeting

Misonix successfully introduced the new BoneScalpel MIS Platform to more than 120 of the world's leading spine surgeons, including several surgeon key opinion leaders ("KOLs") last week at the annual North American Spine Society ("NASS") meeting in Chicago, IL.

10/14/15

### Misonix Unveils New Corporate Branding and BoneScalpel® MIS Platform at 2015 North American Spine Society Annual Meeting

Misonix announced the unveiling of its new Better Matters corporate branding.

09/22/15

### Misonix Appoints Thomas M. Patton to Board of Directors

Misonix announced the addition of Mr. Thomas M. Patton to the Company's Board of Directors. Mr. Patton will replace the vacancy left by the resignation of Thomas O'Neill on May 13, 2015.

**MISONIX, INC.**  
**Income Statement**  
(\$ in Millions Except Per Share Data)

	FY 2012				FY 2013				FY 2014				FY 2015				FY 2016						
	Q1	Q2	Q3	Q4	Q1	FY11	FY12	FY13	FY14	FY15													
	Sep	Dec	Mar	Jun	Sep	Actual	Actual	Actual	Actual	Actual													
<b>Sales by product</b>																							
BoneScalpel	0.656	1.202	1.253	1.654	2.101	1.604	1.126	1.512	1.349	2.108	1.739	2.487	2.207	2.979	2.212	3.686	2.860	2.487	4.764	6.343	7.684	11.084	
SonaStar	1.297	1.330	1.520	1.737	1.573	1.053	1.287	1.398	1.136	1.188	1.578	2.446	1.524	1.697	2.049	1.940	1.424	4.097	5.885	5.311	6.348	7.209	
SonicOne	0.254	0.310	0.214	0.518	0.501	0.528	0.398	0.430	0.469	0.536	0.728	0.494	0.601	0.840	0.847	0.985	0.859	1.105	1.297	1.857	2.227	3.273	
Other	1.010	0.708	0.623	1.392	0.396	0.289	0.212	0.419	0.122	0.289	0.239	0.151	0.208	0.085	0.206	0.139	0.108	4.684	3.733	1.316	0.802	0.638	
Net sales	3.217	3.551	3.610	5.301	4.571	3.474	3.023	3.759	3.076	4.122	4.285	5.578	4.539	5.601	5.315	6.749	5.251	12.373	15.678	14.827	17.060	22.205	
<b>Cost of goods sold</b>	1.453	1.282	1.491	2.241	1.844	1.627	1.482	2.474	1.345	1.229	1.432	1.927	1.586	1.767	1.670	2.257	1.770	5.287	6.467	7.427	5.934	7.280	
Gross Profit	1.764	2.269	2.119	3.060	2.727	1.847	1.541	1.285	1.730	2.893	2.853	3.651	2.953	3.834	3.644	4.493	3.481	7.086	9.211	7.400	11.127	14.924	
Gross margin %	55%	64%	59%	58%	60%	53%	51%	34%	56%	70%	67%	65%	65%	68%	69%	66%	66%	57%	59%	50%	65%	67%	
Selling expenses	1.180	1.194	1.246	1.412	1.459	1.546	1.765	2.007	1.829	1.684	1.914	1.846	2.019	2.085	2.466	2.492	2.637	3.886	5.032	6.776	7.273	9.063	
General and administrative expenses	1.168	1.082	1.024	1.102	1.042	1.093	1.156	1.156	1.221	1.121	1.176	1.173	1.246	1.535	1.583	1.619	1.821	4.500	4.377	4.446	4.691	5.984	
Research and development expenses	0.310	0.304	0.333	0.345	0.397	0.366	0.380	0.353	0.473	0.435	0.406	0.397	0.438	0.324	0.408	0.423	0.393	1.432	1.293	1.496	1.712	1.593	
Total costs and expenses	2.658	2.580	2.603	2.859	2.898	3.005	3.300	3.516	3.523	3.240	3.496	3.417	3.703	3.944	4.457	4.535	4.851	9.817	10.701	12.719	13.676	16.639	
Income (Loss) from operations	(0.89)	(0.31)	(0.48)	0.20	(0.17)	(1.16)	(1.76)	(2.23)	(1.793)	(0.35)	(0.64)	0.23	(0.75)	(0.11)	(0.81)	(0.04)	(1.37)	(2.73)	(1.49)	(5.32)	(2.55)	(1.71)	
Other income (expense):																							
Total other income	0.095	0.332	0.122	0.137	0.211	0.502	1.000	0.683	0.907	0.804	0.826	1.170	1.142	1.040	1.026	1.026	0.982	0.690	0.686	2.397	3.706	4.234	
Pre-tax income	(0.799)	0.021	(0.362)	0.337	0.040	(0.655)	(0.759)	(1.548)	(0.886)	0.457	0.182	1.404	0.393	0.930	0.213	0.984	(0.388)	(2.041)	(0.804)	(2.922)	1.157	2.519	
Income tax expense (benefit)	0.005	(0.207)	(0.086)	0.093	0.002	0.002	(0.059)	(0.020)	0.003	0.003	0.008	0.017	0.014	0.033	0.008	(2.841)	(0.168)	0.064	(0.195)	(0.075)	0.031	(2.785)	
Net income (loss) from continuing operations	(0.804)	0.228	(0.276)	0.244	0.039	(0.657)	(0.700)	(1.528)	(0.889)	0.454	0.174	1.387	0.378	0.896	0.205	3.825	(0.220)	(2.105)	(0.609)	(2.847)	1.127	5.304	
Shares Outstanding (Basic)	7,001,370	7,001,370	7,001,404	7,003,588	7,005,360	7,020,107	7,060,965	7,115,557	7,182,866	7,195,406	7,249,725	7,301,157	7,361,555	7,567,442	7,675,520	7,721,489	7,748,509	7,001,370	7,001,930	7,050,423	7,232,004	7,580,450	
Shares Outstanding (Diluted)	7,001,370	7,001,370	7,001,404	7,046,790	7,297,690	7,020,107	7,060,965	7,115,557	7,182,866	7,712,903	7,930,802	7,684,842	7,644,434	8,170,821	8,313,674	8,247,545	7,748,509	7,001,370	7,001,930	7,050,423	7,467,592	8,094,119	
EPS (Basic)	(0.11)	0.03	(0.04)	0.03	0.01	(0.09)	(0.07)	(0.22)	(0.12)	0.06	0.06	0.19	0.05	0.12	0.06	0.50	(0.03)	(0.30)	(0.09)	(0.38)	0.19	0.74	
EPS (Diluted)	(0.11)	0.03	(0.04)	0.03	0.01	(0.09)	(0.07)	(0.22)	(0.12)	0.06	0.05	0.18	0.05	0.11	0.05	0.46	(0.03)	(0.30)	(0.09)	(0.38)	0.19	0.69	

# Misonix, Inc. (Nasdaq: MSON)

Medical Appliances & Equipment

December 2015

## MISONIX, INC. Balance Sheet (\$ in millions)

	FY 2012				FY 2013				FY 2014				FY 2015				FY 2016				
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	
	Sep	Dec	Mar	Jun	Sep	Dec	Mar	Jun	Sep	Dec	Mar	Jun	Sep	Dec	Mar	Jun	Sep	Dec	Mar	Jun	
	Actual	Actual	Actual	Actual	Actual	Actual	Actual														
<b>ASSETS</b>																					
<b>Current assets:</b>																					
Cash and cash equivalents	6.207	6.697	5.931	6.273	6.663	6.855	6.092	5.806	4.654	5.034	5.648	7.040	7.598	8.296	8.909	9.624	9.745	6.273	5.806	7.040	9.624
Accounts receivable	2.051	1.876	2.001	3.158	2.612	2.329	2.788	2.975	2.799	2.871	2.955	3.759	3.306	3.575	3.518	4.481	3.703	3.158	2.975	3.759	4.481
Inventories, net	3.880	3.658	4.580	4.381	4.211	4.373	4.448	4.034	4.157	3.970	4.119	4.217	4.534	4.252	4.164	4.303	4.811	4.381	4.034	4.217	4.303
Prepaid expenses and other current assets	0.268	0.172	0.376	0.307	0.224	0.196	0.328	0.387	0.294	0.210	0.362	0.368	0.300	0.169	0.530	0.442	0.338	0.307	0.387	0.368	0.442
Note receivable	0.460	0.411	0.205	0.198	0.075	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.198	0.000	0.000	0.000
Deferred income tax-current	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	2.119	2.275	0.000	0.000	0.000	2.119
Current assets of discontinued operations	0.000	0.498	0.085	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Total current assets	12.865	13.312	13.178	14.317	13.785	13.752	13.656	13.203	11.904	12.084	13.084	15.384	15.738	16.292	17.121	20.968	20.873	14.317	13.203	15.384	20.968
Property and equipment, net	1.069	0.959	0.946	0.892	0.809	0.779	1.173	1.327	1.185	1.305	1.508	1.518	1.549	1.708	1.894	2.057	2.164	0.892	1.327	1.518	2.057
Patents, net	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.566	0.564	0.000	0.000	0.000	0.000
Goodwill	1.701	1.701	1.701	1.701	1.701	1.701	1.701	1.701	1.701	1.701	1.701	1.701	1.701	1.701	1.701	1.701	1.701	1.701	1.701	1.701	1.701
Intangible and other assets	1.808	1.748	1.673	1.403	1.343	1.277	1.193	1.129	1.074	1.031	0.962	0.925	0.825	0.854	1.107	0.388	0.279	1.403	1.129	0.925	0.954
Deferred income tax-long term	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.774	0.767	0.000	0.000	0.000	0.774
Assets of discontinued operations	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Total assets	17.443	17.720	17.498	18.313	17.638	17.508	17.724	17.360	15.864	16.121	17.255	19.528	19.813	20.555	21.823	26.454	26.348	18.313	17.360	19.528	26.454
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>																					
<b>Current liabilities:</b>																					
Accounts payable	1.971	1.041	1.173	1.508	0.926	1.271	1.368	2.209	1.601	1.155	1.323	1.650	1.434	1.050	1.023	1.147	1.143	1.508	2.209	1.650	1.147
Accrued expenses and other current liabilities	1.230	1.109	1.059	1.075	0.849	0.873	1.203	1.277	1.025	1.063	1.198	1.457	1.306	1.213	1.357	1.532	1.219	1.075	1.277	1.457	1.532
Liabilities of discontinued operations	0.000	0.229	0.062	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Total current liabilities	3.201	2.379	2.294	2.583	1.775	2.144	2.571	3.486	2.626	2.218	2.520	3.108	2.740	2.262	2.381	2.680	2.362	2.583	3.486	3.108	2.680
Deferred lease liability	0.016	0.019	0.021	0.023	0.023	0.023	0.024	0.024	0.022	0.020	0.018	0.017	0.042	0.008	0.004	0.000	0.002	0.023	0.024	0.017	0.000
Deferred income	0.150	0.139	0.128	0.117	0.106	0.095	0.084	0.073	0.062	0.075	0.062	0.051	0.012	0.036	0.028	0.020	0.013	0.117	0.073	0.051	0.020
Total liabilities	3.368	2.537	2.443	2.723	1.904	2.262	2.678	3.583	2.710	2.313	2.601	3.176	2.794	2.306	2.413	2.700	2.377	2.723	3.583	3.176	2.700
<b>Shareholders' equity:</b>																					
Capital stock	0.071	0.071	0.071	0.071	0.071	0.071	0.072	0.072	0.073	0.073	0.074	0.074	0.076	0.078	0.078	0.079	0.079	0.071	0.072	0.074	0.079
Additional paid-in capital	25.870	25.958	26.043	26.133	26.232	26.398	26.724	26.990	27.250	27.445	27.861	28.170	28.674	29.313	30.019	30.531	30.968	26.133	26.990	28.170	30.531
Accumulated deficit	(11.453)	(10.433)	(10.648)	(10.203)	(10.158)	(10.812)	(11.340)	(12.874)	(13.758)	(13.298)	(12.870)	(11.480)	(11.097)	(10.196)	(9.742)	(5.909)	(6.129)	(10.203)	(12.874)	(11.480)	(5.909)
Treasury stock	(0.412)	(0.412)	(0.411)	(0.411)	(0.411)	(0.411)	(0.411)	(0.411)	(0.411)	(0.411)	(0.411)	(0.411)	(0.633)	(0.946)	(0.946)	(0.946)	(0.946)	(0.411)	(0.411)	(0.411)	(0.946)
Total stockholders' equity	14.076	15.183	15.055	15.590	15.734	15.246	15.045	13.777	13.154	13.808	14.654	16.352	17.019	18.248	19.410	23.754	23.971	15.590	13.777	16.352	23.754
Total liabilities and stockholders' equity	17.443	17.720	17.498	18.313	17.638	17.508	17.724	17.360	15.864	16.121	17.255	19.528	19.813	20.555	21.823	26.454	26.348	18.313	17.360	19.528	26.454

PLEASE SEE THE IMPORTANT DISCLOSURES ON THE LAST PAGE OF THIS REPORT.

### **Misonix, Inc. Management**

#### ***Michael A. McManus, Jr.***

##### ***President and Chief Executive Officer***

Michael McManus, Jr. became President and Chief Executive Officer of the Company in November 1999. From November 1991 to March 1999, Mr. McManus was President and Chief Executive Officer of New York Bancorp, Inc. Prior to New York Bancorp, Inc., Mr. McManus held senior positions with Jamcor Pharmaceutical, Inc., Pfizer, Inc. and Revlon Corp. Mr. McManus also spent several years as an Assistant to President Reagan. Mr. McManus serves on the Board of Directors of the following publicly traded companies: American Home Mortgage Holdings, Inc.; Liquid Audio, Inc.; Novavax, Inc.; and NWH, Inc. Mr. McManus holds a B.A. degree in Economics from the University of Notre Dame and a Juris Doctorate from Georgetown University Law Center.

#### ***Richard Zaremba***

##### ***Senior Vice President & CFO***

Richard Zaremba became Vice President and Chief Financial Officer in February 1999. From March 1995 to February 1999, he was the Vice President and Chief Financial Officer of Converse Information Systems, Inc., a manufacturer of digital voice recording systems. Previously, Mr. Zaremba was Vice President and Chief Financial Officer of Miltope Group, Inc., a manufacturer of electronic equipment. Mr. Zaremba is a licensed certified public accountant in the state of New York and holds BBA and MBA degrees in Accounting from Hofstra University.

#### ***Scott Ludecker***

##### ***Senior Vice President, Global Sales and Marketing***

Scott Ludecker, Senior Vice President of Global Sales and Marketing will oversee all sales and marketing activities for Misonix worldwide. With more than 20 years of experience in the global medical device industry, Scott Ludecker has a demonstrated track record of successfully commercializing medical technology and in building and managing global sales distribution networks. Mr. Ludecker most recently served as Vice President of Global Sales and Marketing for BioMimetic Therapeutics, a NASDAQ-listed biotechnology company, specializing in the development and commercialization of products which promote the healing of musculoskeletal injury and diseases, including orthopedic, spine, and sports medicine applications. Mr. Ludecker is a graduate of Kenyon College with a BA degree in Political Science.

#### ***John Salerno***

##### ***Vice President of Regulatory Affairs***

John Salerno joined Misonix Inc. as Vice President, Quality Assurance and Regulatory Affairs in March 2015. Mr. Salerno has over 35 years of experience in quality assurance, quality engineering, quality systems, regulatory compliance and regulatory affairs for the pharmaceutical, medical device, in-vitro diagnostic and cosmetic industries. He has held senior positions with International Technidyne Division of Thoratec Corporation, Pall Corporation and Rugby-Darby Group Companies and has consulted for Becton Dickinson Corporation, Bausch and Lomb Corporation and Novartis. Mr. Salerno holds a B.S. in Biology from Fordham University and a M.S. in Microbiology from Long Island University.

#### ***Dan Voic***

##### ***Vice President of Research and Development and Engineering***

Mr. Voic became Vice President of Research and Development and Engineering in January 2002. Prior thereto, he served as Engineering Manager and Director of Engineering with the Company. Mr. Voic has approximately 14 years experience in both medical and laboratory and scientific products development. Mr. Voic holds a M.S. degree in mechanical engineering from Polytechnic University "Traian Vuia" of Timisoara, Romania and a MS degree in applied mechanics from Polytechnic University of New York.

#### ***Joe Brennan***

##### ***Vice President of Operations***

Joseph Brennan joined Misonix Corporation in August of 2014 as Vice President of Operations. Most recently, he served as Director of Operations for Air Techniques Inc., a vertically integrated manufacturer of air products for the dental operatory and digital imaging products for dental, medical and veterinary applications. Mr. Brennan has 30 years of diversified manufacturing experience. He holds degrees in Mechanical Engineering and Manufacturing Engineering from Farmingdale State University.

#### ***Michael L. Consilvio***

##### ***Vice President of Marketing***

Michael L. Consilvio became Vice President of Marketing in July 2105. Prior to joining the Company, Mr. Consilvio served from 2008 to 2015, most recently in the position of Director of International Commercializations, with Biomet Spine. From 2007 – 2008 Mr. Consilvio held the position of worldwide director of Marketing and Medical Education with Small Bone Innovations. From 2004 – 2007 he held the position of Group Product Director for the Musculoskeletal Transplant Foundation. Prior to 2004, Mr. Consilvio held positions with various organizations in the Orthopedics field. Mr. Consilvio holds a Masters degree in Corporate Finance from Fairleigh Dickinson University and a Bachelor's Degree in Economics from the State University of New York at Oneonta.

### Misonix Safe Harbor Statement

With the exception of historical information contained in this document, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

### Lytham Partners Disclaimer

Lytham's compensation for providing investor relations services to the company consists of a cash fee ranging from approximately \$4,000 to \$10,000 per month.

●●● As of the date of this report, Lytham owns 0 shares of Misonix stock. However, this is subject to change from time to time in the future without notice.

●●● Upon the completion of various criteria, Lytham may be granted options to purchase up to 10,000 shares of Misonix stock. ●●● Lytham or any of its affiliates, members, employees, clients, officers, directors, and/or their respective families may from time to time purchase or sell, or otherwise hold positions in, securities of the company, and are free to buy or sell those positions at will. Any such positions may be increased or decreased from time to time in the future without notice. ●●● Lytham is not, and does not hold itself out to be, a registered broker-dealer, registered investment adviser or financial adviser. ●●● The information in this report is not to be regarded as investment advice and is only for informative purposes. This report does not constitute an endorsement of the company. None of the information in this report is intended to be used as a basis for any investment decision, and the information is subject to change without notice. ●●● Before making a purchase or sale of any securities mentioned in this report, Lytham strongly encourages and recommends consultation with a registered securities representative. ●●● This report does not constitute an offer to purchase or sell securities, and is not to be construed as a representation of an offer or a solicitation of any offer by Lytham or by the company to purchase or sell any security. ●●● Certain information in this report may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), as well as Regulation FD, and is taken from materials available to the general public, including the subject company's filings with the SEC, documents included on the subject company's website, information provided by the subject company or from other publicly available sources deemed reliable by Lytham. Lytham does not represent or guarantee the accuracy or completeness of the information. These statements may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors which could cause or contribute to such differences are detailed in the company's public filings with the United States Securities and Exchange Commission. ●●● Forward-looking statements speak only as of the date the statement was made. The company does not undertake and specifically disclaims any obligation to update any forward-looking statements. The company claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. ●●● Any performance data quoted represents past performance of the company. There is no guarantee of comparable future results; current performance may be more or less favorable. The information in this report is subject to change without notice and Lytham assumes no responsibility to update the information.



**PHOENIX**  
City Square  
3800 N. Central Ave.  
Suite 750  
Office 602.889.9700  
Fax 602.889.9696

[www.lythampartners.com](http://www.lythampartners.com)

**NEW YORK**  
750 Third Avenue  
9th Floor  
New York, NY 10017  
Office 646.829.9700  
Fax 646.829.9701

[info@lythampartners.com](mailto:info@lythampartners.com)